Ftse Mib
34.608,59
-0,62%
DAX
18.726,76
-0,21%
S&P 500
5.316,26
0,15%
NASDAQ
16.808,51
0,08%
Bitcoin
69.754,99
-2,37%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CASI Pharmaceuticals Inc (CASI) CASI Pharmaceuticals Inc (CASI) Notizie

CASI

CASI Pharmaceuticals (CASI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CASI
DataOraFonteTitoloSimboloCompagnia
15/05/202414:00PR Newswire (US)CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)NASDAQ:CASICASI Pharmaceuticals Inc
15/05/202412:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
14/05/202414:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
13/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CASICASI Pharmaceuticals Inc
08/04/202423:00PR Newswire (US)CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASNASDAQ:CASICASI Pharmaceuticals Inc
28/03/202412:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
05/03/202413:00PR Newswire (US)CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaNASDAQ:CASICASI Pharmaceuticals Inc
16/02/202413:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
14/11/202313:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
08/11/202313:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPANASDAQ:CASICASI Pharmaceuticals Inc
11/08/202313:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
01/08/202313:00PR Newswire (US)Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsNASDAQ:CASICASI Pharmaceuticals Inc
20/07/202314:00PR Newswire (US)CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339NASDAQ:CASICASI Pharmaceuticals Inc
17/05/202313:35PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
26/04/202315:49PR Newswire (US)CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022NASDAQ:CASICASI Pharmaceuticals Inc
26/04/202314:27Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:CASICASI Pharmaceuticals Inc
26/04/202313:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
22/03/202311:04Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202322:08Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202321:51Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202321:42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202321:30PR Newswire (US)CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGERNASDAQ:CASICASI Pharmaceuticals Inc
09/02/202316:49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
06/01/202313:00PR Newswire (US)CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
15/12/202213:00PR Newswire (US)CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNASDAQ:CASICASI Pharmaceuticals Inc
16/11/202208:57TipRanksBTIG Sticks to Their Buy Rating for CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
14/11/202213:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
28/09/202212:25TipRanksH.C. Wainwright Remains a Buy on CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
23/09/202213:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETNASDAQ:CASICASI Pharmaceuticals Inc
09/09/202222:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CASICASI Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CASI

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
G
Generali
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
TITR
Telecom Italia
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network